Quarterly report pursuant to Section 13 or 15(d)

INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative)

v3.10.0.1
INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 12, 2018
Jul. 28, 2016
Jan. 26, 2016
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Intellectual property fees     $ 55,648          
Description for right to purchase perpetual rights     <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">North America with the option for Central and South America for Naltrexone Implants formulas created by the Seller for 24 months upon receipt of the intellectual property for a fee of $55,648. The Company, within the first 12 months has the right to purchase perpetual rights for above territories for a one-time fee, financed over 5 years. The rights are amortized over the 24 month contract life.</font></p>          
Amortization expenses       $ 0 $ 7,013 $ 1,963 $ 20,810  
Therakine, Ltd. [Member]                
License cost   $ 2,750,000            
Aggregate purchase price   $ 250,000       $ 250,000   $ 250,000
Escrow deposit               $ 75,000
Therakine, Ltd. [Member] | Minimum [Member]                
Milestone payments and royalties   5.00%            
Therakine, Ltd. [Member] | Maximum [Member]                
Milestone payments and royalties   12.00%            
Subsequent Event [Member] | Therakine Biodelivery GmbH [Member]                
Patent acquired $ 15,200              
Development, Commerialization and License agreement, description <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Patent families consisting of approximately 11 patents pending and 1 issued patent.</font></p>